NCT07500727Recruiting
Skeletal Muscle Aging and Responsiveness in Aged People With MS
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
The purposes of this study are to: 1) compare baseline muscle and cardiovascular health in older individuals (\>60 years old) diagnosed with MS to age-matched people without MS, 2) determine muscle and whole body changes to an exercise training program, 3) determine if the muscle in a more affected leg in individuals diagnosed with MS is different from the muscle of a less affected leg, and 4) if or how individuals diagnosed with MS adapt differently than age-matched people without MS to exercise training. Participation in this study will average 1.5 hours per visit, 3 visits per week, for approximately 4 months.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 10 Mar 2026
- Start date
- 6 Mar 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Oklahoma Medical Research Foundation
- Diseases
- Multiple sclerosis
- NCT number
- NCT07500727
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 6 Mar 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- 1\. Neuromuscular or musculoskeletal disorder, other than multiple sclerosis, that would limit the ability to perform the exercise and/or testing bouts.
- 2\. Cardiopulmonary disorders or reduced breathing capacity
- 3\. Metabolic diseases including markers of liver disease (ALT \> 52 U/dl) and type 2 diabetes (HbA1C ≥ 6.5, fasting blood glucose ≥ 126 mg/dl)
- 4\. Taking any dose of metformin
- 5\. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, Alzheimer's, current cancer diagnosis or within 2 yr remission, cerebrovascular)
- 6\. History of Chemotherapy within 5 years
- 7\. Unchangeable anticoagulant (Coumadin, Pradaxa, etc.) use. To be determined by clinical staff.
- 8\. Insulin sensitizing/blood glucose lowering (e.g., metformin) or metabolic (GLP1 agonists) drugs.
- 9\. High dose statin (40 mg and above)
- 10\. Have a non-correctable visual impairment
- 11\. Score less than 29 on the Symbol Digit Test
- 12\. Received Botox for spasticity within the prior 3 months of study participation.
- 13\. Cannot have any adjustments to Baclofen during study participation.
- 13\. Unable to commit to \~4 months required to complete the study.
- 14\. Lidocaine allergy
- 15\. Tobacco use
- 16\. Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/day or drinks/wk for males)
- 17\. BMI greater than 35.0 kg/m2
Who the study is looking for
- 1\. Male or female aged 60 or above 2. Free of unmanaged chronic diseases other than multiple sclerosis 3. No structured exercise program (2 or more bouts/wk) within previous 6 months 4. Cognitively capable of providing informed consent 5. Must meet EDSS score between 2 to 5.5 during screening
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oklahoma Medical Research Foundation Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.